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Abstract
The aim of this chapter is to increase the awareness of health‐care professionals concerning 
potential adverse effects and drug interactions of non‐steroidal anti‐inflammatory drugs 
(NSAIDs), which are among the most widely prescribed medicines, globally. They have 
a variety of clinical applications due to their anti‐inflammatory, analgesic, antipyretic, 
or antithrombotic effect, but these drugs are not entirely innocuous, since they could 
increase the risk of gastrointestinal and cardiovascular complications. Furthermore, the 
drugs from this class have the potential of altering the pharmacokinetics of associated 
drugs, and also pharmacodynamic interactions have been reported. The clinical signifi‐
cance, mechanisms, and epidemiology of the adverse effects and drug interactions of 
NSAIDs are presented in this chapter. Prevention strategies for particularly high‐risk 
groups of patients are also exposed. Detailed and up‐to‐date information regarding the 
adverse effects and drug interactions of NSAIDs are needed for all healthcare profession‐
als in order to maximize efficacy in treating various illnesses while minimizing the risks 
for the patients.
Keywords: NSAIDs, gastrointestinal, cardiovascular adverse effects, nephropathy, 
hepatotoxicity, drug interactions
1. Introduction
The non‐steroidal anti‐inflammatory drugs (NSAIDs) are among the most successful medi‐
cines in the world, being used by large numbers of patients, due to their anti‐inflammatory, 
analgesic, and antipyretic effects. Since the discovery of acetylsalicylic acid (aspirin) in the 
nineteenth century by F. Hoffmann, more than 50 different molecules have been marketed 
worldwide. NSAIDs are usually prescribed in chronic inflammatory conditions, but they are 
also extensively used as over‐the‐counter (OTC) drugs in a variety of inflammatory processes, 
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mild‐to‐moderate pain or fever. Other clinical uses (e.g. low‐dose aspirin for cardioprotection) 
are also very popular.
Chemically, NSAIDs are extremely heterogeneous: salicylic acid derivatives (aspirin, diflunisal), 
indoles (indomethacin), fenamic acid derivatives (mefenamic acid, meclofenamic acid), acetic 
acid derivatives (diclofenac, ketorolac), propionic acid derivatives (ibuprofen, ketoprofen, 
naproxen), enolic acid derivatives (piroxicam, meloxicam), or diaryl heterocyclic compounds 
(celecoxib, etoricoxib) [1]. Most of the NSAIDs are organic acids, with low pKa values, capable 
of accumulation in the inflamed tissues, characterized by acidic pH.
Pharmacologically, all NSAIDs share a common mechanism of action, discovered by J.R. Vane 
in 1971: they act as competitive and reversible inhibitors of Prostaglandin G/H synthase (also 
known as cyclooxygenase or COX), thus reducing the formation of various prostaglandins [2]. 
The only exception is acetylsalicylic acid (aspirin), which irreversibly acetylates a key amino 
acid (serine 529) situated in the active site of COX‐1, with the formation of a covalent bond, 
which leads to permanent enzyme inhibition. A series of studies characterized at least two 
isoforms of COX in humans:
• COX‐1, a constitutive enzyme, normally expressed in many cells, which generates prosta‐
glandins directly involved not only in the protection of gastric mucosa but also in platelet 
and renal homeostasis. The inhibition of this isoform is considered to be responsible for the 
gastric adverse effects of non‐selective NSAIDs.
• COX‐2, induced by pro‐inflammatory cytokines or aggression of the tissues, which generates 
prostaglandins involved in pain, fever, and inflammation. Also, COX‐2 can be responsible 
for some physiological functions.
Depending on the relative selectivity for COX isoforms, two types of NSAIDs have been 
developed:
• Non‐selective (traditional) NSAIDs (ibuprofen, diclofenac, indomethacin, etc.), which 
 inhibit both isoforms of COX, with high potential of inducing gastric irritation.
• COX‐2 selective drugs (coxibs, nimesulide, meloxicam), which selectively inhibit COX‐2, 
better tolerated by the gastric mucosa, but with different safety issues.
A key feature of NSAID class is that, partially, both beneficial and adverse effects are caused 
by the same mechanism of action: inhibition of prostaglandin biosynthesis [1, 3].
2. Adverse effects of NSAIDs
The adverse drug reactions (ADRs) are a major health issue worldwide, causing frequent 
 hospital admissions and being one of the leading causes of mortality [4]. Although adverse 
effects of non‐steroidal anti‐inflammatory drugs (NSAIDs) affect a limited percentage of 
users, the widespread use of these medicines can cause significant health problems. The 
probability of suffering severe adverse effects is correlated with the dose and the age of the 
patients, the elderly being more vulnerable. Lower starting doses and reduction of doses in 
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patients at risk are good preventive strategies, but further studies are necessary in order to 
develop genetic or biochemical markers of NSAID toxicity, in order to better anticipate the 
advent of an unwanted drug‐induced adverse effect [5].
The adverse effects of NSAIDs can be manifested at different levels.
2.1. Gastrointestinal
The gastrointestinal (GI) adverse effects of NSAIDs are considered to be a hallmark of 
this pharmacological class, affecting 10–60% of patients [6]. They can include an array 
of symptoms and manifestations varying in severity from simple dyspepsia with pyrosis 
to fully developed gastric or intestinal ulcer. The ulcerations can become complicated with 
acute bleeding and perforation, a life‐threatening situation. The most frequent adverse 
effects of NSAIDs at gastrointestinal level together with the additional risk factors are 
presented in Table 1.
The propensity of NSAIDs to induce gastrointestinal adverse effects depends on the 
 molecule and mode of action. The non‐selective NSAIDs frequently cause gastrointestinal 
damage, while the COX‐2 selective NSAIDs have a dramatically improved gastric toler‐
ability. The mechanism of NSAID‐induced gastrointestinal damage has been extensively 
studied [5, 6].
The non‐selective NSAIDs can induce lesions of the gastrointestinal mucosa by a topical 
erosive effect combined with a systemic effect characterized by depletion of prostaglandins 
synthesized by COX‐1 (Figure 1). Normally, these “good” prostanoids stimulate the synthe‐
sis and secretion of mucus and bicarbonate, increase the blood flow, and promote epithe‐
lial proliferation. By removing these beneficial effects, non‐selective NSAIDs create a gastric 
 environment more susceptible to topical erosion by exogenous and endogenous factors. Thus, 
the acidic properties of most NSAIDs initiate mucosal damage because the drug molecules 
remain in a non‐ionized lipophilic form in the acid environment of the stomach, entering into 
surface epithelial cells where they dissociate, trapping hydrogen ions and inducing lesions. 
The NSAID molecules additionally reduce the hydrophobicity of gastric mucus, allowing the 
hydrochloric acid and pepsin to attack the surface epithelium [5, 6].
Also, the decrease of TXA2, process which can subsequently favor bleeding, is an additional 
mechanism of NSAID‐induced gastric damage.
Affected organ system Symptoms and manifestations Additional risk factors
Gastrointestinal tract Dyspepsia with pyrosis, Abdominal 
pain, Nausea, Anorexia, Gastric 
erosions, Ulcers, Perforation, 
Gastrointestinal hemorrhage, Anemia
History of GI ulcer, Helicobacter 
pylori, Age above 60, High doses 
of NSAIDs, Use of anticoagulants 
and corticosteroids, Use of multiple 
NSAIDs
Adapted from Refs. [1, 6].
Table 1. Adverse effects of NSAIDs at gastrointestinal level and additional risk factors.
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Whether the direct, topical erosive effect of non‐selective NSAIDs or the systemic depletion 
of “good” prostaglandins is the key factor responsible for the apparition of gastrointestinal 
damage, is still a matter of controversy.
Several large‐scale epidemiological studies have been performed to gather valuable informa‐
tion regarding the gastrointestinal (GI) safety profile of the NSAID class.
For the non‐selective NSAIDs, the Arthritis, Rheumatism, and Ageing Medical Information 
Systems (ARAMIS) study reported that the rate of gastrointestinal events was six times higher 
in patients taking NSAIDs than in non‐users [7]. The meta‐analysis of Gabriel et al. indicated 
that the relative risk (RR) of the first gastrointestinal event is 2.4 (CI 95%: 2.2–2.7) but becomes 
4.8 (CI 95%: 4.0–5.6) if a previous history of ulcer exists [8]. Also, another study identified that 
the relative risk for adverse GI events increased with age, from 1.8 in younger patients to 3.5 
in patients between 60 and 75 years old [9].
Furthermore, the Paracetamol, Aspirin, and Ibuprofen New Tolerability (PAIN) study 
 demonstrated that ibuprofen (<1200 mg/day) was similar to acetaminophen (<3000 mg/day) 
in terms of the incidence of significant GI adverse effects and that statistically significant fewer 
events were associated with ibuprofen in comparison with aspirin (<3000 mg/day)  during 1–7 
days of treatment [10].
For the COX‐2 selective NSAIDs, the Celecoxib Long‐Term Arthritis Safety Study (CLASS) 
trial randomized patients with rheumatoid arthritis to either celecoxib 400 mg twice daily, 
ibuprofen 800 mg three times daily, or diclofenac 75 mg twice daily. After 6 months, significantly 
lower GI events were seen in celecoxib group (RR 0.59; 95% CI: 0.38–0.94) [11].
Figure 1. Mechanisms of NSAID‐induced gastrointestinal damage.
Nonsteroidal Anti-Inflammatory Drugs20
For etoricoxib, gastrointestinal adverse events were evaluated by combined analysis of 10 
clinical trials enrolling 3142 patients. According to this study, etoricoxib halves both perfora‐
tion and confirmed and unconfirmed bleeding, compared to non‐selective NSAIDs [12].
Finally, a meta‐analysis of 112 large‐scale randomized clinical trials revealed that the risk 
of ulcer and serious GI complications associated with coxibs were lower than non‐selective 
NSAIDs (RR 0.49; 95% CI: 0.38–0.62 vs. RR 0.55; 95% CI: 0.38–0.80) [13].
The management of patients receiving NSAIDs regarding gastrointestinal toxicity should 
take into consideration several key facts [5, 14]:
• The lowest dose should be used for the shortest period of time.
• Simultaneous administration of anticoagulants and corticosteroids should be avoided.
• Helicobacter pylori infection should be eradicated if present.
• NSAIDs with high GI toxicity (piroxicam, ketoprofen, ketorolac) should be avoided.
• The gastric damage can be reduced by associating NSAIDs with misoprostol or proton 
pump inhibitors (PPIs).
• If no gastrointestinal risk factors are present, non‐selective NSAIDs are preferred.
• If one or more GI risk factors are present, coxibs should be used or non‐selective NSAIDS 
+ proton pump inhibitors (PPIs).
2.2. Cardiovascular
Based on currently available data, regulatory agencies from EU (EMEA) and USA (FDA) 
have concluded that an increased risk for unwanted cardiovascular (CV) events has been 
demonstrated for all the COX‐2 selective NSAIDs. The cardiovascular events have a throm‐
botic nature, being either acute myocardial infarctions (AMI) or strokes. Also, non‐selective 
NSAIDs have a potential of causing unwanted CV events, especially when used in high doses 
and for longer periods of time.
As a consequence, the Food and Drug Administration (FDA) has requested that all COX‐2 
selective NSAIDs should be labeled with a boxed warning regarding increased risk of  serious 
CV thrombotic events and a contraindication for patients who have recently undergone a 
CABG procedure. For non‐selective NSAIDs, FDA has concluded that short‐term use is not 
associated with increased CV risk, but the labeling should mention the potential risk [14].
COX‐2 selective NSAIDs, especially the coxibs (rofecoxib‐removed from market, celecoxib, 
etoricoxib), inhibit the synthesis of vascular prostacyclin (PGI2), a natural inhibitor of platelet 
aggregation with vasodilator properties. PGI2 is a protective mediator for cardiovascular sys‐
tem, acting via its receptor IP, expressed in different cell types. The increased risk of vascular 
events caused by the reduction of PGI2 formation might be mitigated by a simultaneous 
suppression of COX‐1 in the platelets. Unfortunately, COX‐2 selective drugs, having no 
affinity for COX‐1, do not reduce the platelet production of thromboxane A2 (TXA2) (Figure 2). 
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Combined, these two effects may lead to a “pro‐thrombotic state” with a significant risk of 
developing myocardial infarction or stroke [5]. However, with the exception of naproxen, 
neither of the non‐selective NSAIDs (apart from aspirin) could affect platelet COX‐1 in such a 
significant manner necessary for a platelet inhibitory effect [15].
Multiple large‐scale epidemiological studies have been performed to gather data regarding 
the cardiovascular (CV) safety profile of the NSAID class.
A comparative analysis of patients with arthritis receiving celecoxib 400 mg twice daily 
and patients receiving placebo in an aspirin primary prevention meta‐analysis showed that 
the annualized rate for acute myocardial infarction (AMI) was higher in patients receiving 
 celecoxib compared to placebo (0.80 vs. 0.50) [16].
In a meta‐analysis of three large observational studies, etoricoxib was associated with a sig‐
nificant 97% increase risk of AMI [17].
For the non‐selective drugs, several epidemiological studies have provided conflicting 
results. For ibuprofen, studies evaluating potential risk for CV events ranged from show‐
ing no risk (RR 0.96; 95% CI: 0.81–1.14) to a significantly increased risk (HR 1.84; 95% CI: 
1.62–2.08) [18].
For naproxen, studies ranged from showing a decreased risk (RR 0.75; 95% CI: 0.62–0.92) to 
significantly increased risk (OR 1.27; 95% CI: 1.01–1.60) [19].
More recently, a large meta‐analysis of 754 RCTs (350,000 patients) concluded that diclofenac 
(150 mg daily) presents similar risks to COX‐2 selective drugs for mortality (RR 1.02; 95% 
Figure 2. Mechanism of COX‐2 selective NSAIDs‐induced thrombosis.
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CI: 0.84–1.24) but naproxen (1000 mg daily) is associated with fewer CV events and lower 
mortality [20].
On the basis of evidence gathered so far, several strategies for NSAID treatment and CV 
 prevention have been suggested [5, 14]:
• Patients with low CV risk (under 1%/year) can be administered either a non‐selective 
NSAID or a coxib, the choice between the two depending on the GI risk.
• In patients with intermediate CV risk (1–3%/year), the choice should be ibuprofen or 
naproxen (+PPI).
• In patients with high CV risk (above 3%/year), the choice is naproxen +PPI and aspirin, 
given 2 hours before.
• In Europe, EMEA contraindicates coxibs if cardiovascular risk factors are present.
2.3. Renal
In normal human subjects, NSAIDs do not have a significant influence on renal function. 
Nevertheless, prostaglandins are important mediators at the kidney level. They are involved 
in maintaining the volume control and electrolyte balance, they also control the release of 
renin and contribute to renal vasodilation. All NSAIDs can alter renal function by inhibit‐
ing COX‐1 (which regulates renal hemodynamics and glomerular filtration) and/or COX‐2 
(which mediates salt and water excretion) expressed in the kidneys [21].
Usually, NSAIDs are associated with salt and water retention, due to the loss of PG‐induced 
action on ADH. This hydro‐saline retention has the potential of triggering arterial hyperten‐
sion, but the effect varies greatly among the different molecules. Apparently, indomethacin 
and naproxen may increase the mean arterial pressure with 3–4 mm Hg [22].
Rarely, NSAIDs can cause a nephropathy, favored by high doses of multiple drugs but also 
in patients with congestive heart failure, chronic kidney disease, hypovolemia, disorders of 
the RAAS system. The manifestations of nephropathy may vary (e.g. interstitial nephritis, 
nephrotic syndrome, and papillary necrosis), and, unfortunately, it can progress to acute 
renal failure [23]. Of the available NSAIDs, indomethacin is the most potent inhibitor of renal 
prostaglandins, therefore being associated with more cases of renal failure. Drugs with an 
intermediate risk include ibuprofen, naproxen, diclofenac, sulindac, and piroxicam [24]. The 
nephrotoxic potential of COX‐2 selective drugs is less clear.
2.4. Hepatic
Hepatotoxicity is a rare adverse effect of NSAIDs, but with potential serious consequences. 
A series of clinical trials have reported transient elevations of liver transaminases during the 
treatment with NSAIDs, but the values have usually normalized in time. Only in a minority 
of patients, a significant liver injury was observed, with symptoms which included nausea, 
vomiting, upper abdominal pain, fatigue, and jaundice. The injuries were primarily choles‐
tatic, but hepatocellular or mixed cases were also documented [25].
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Two large cohort studies pinpointed a 9/100,000 patients ratio of developing NSAID‐associ‐
ated hepatotoxicity. In the first study, out of 228,392 patients taking diclofenac, indomethacin, 
naproxen, sulindac, or piroxicam, 34 cases of acute liver injury were identified. The relative 
risk of developing liver injuries increased in patients with rheumatic diseases (RR 10.9; 95% 
CI: 2.4–50.2). Age and gender did not increase the relative risk [26]. The second study involved 
625,307 patients from England and Wales, only 23 cases of acute liver injury being identified. 
Only sulindac was associated with a significant risk [27].
Nimesulide, a COX‐2 selective NSAID marketed in Europe, was also associated with an 
increased risk of liver toxicity, but the European Medicines Agency (EMA) concluded in 2011 
that the benefit/risk ratio remains positive for patients with acute pain or primary dysmenor‐
rhea [28, 29].
2.5. Blood
Non‐steroidal anti‐inflammatory drugs (NSAIDs) can affect platelet aggregation and bleeding 
time due to inhibition of PG and TXA2 synthesis. Aspirin is the most potent compound in this 
respect, due to the irreversible inhibition of COX‐1 from the platelets, which translates into 
an increase in bleeding time. For aspirin, prolongation of bleeding time is about twice that 
of baseline in healthy subjects after a single dose of 325 mg. The effect begins 12 hours after 
a dose, and lasts between 24 and 48 hours. The other drugs from the class can also increase 
bleeding time, but the values are situated in the upper limit of the normal [30].
2.6. Hypersensitivity
Non‐steroidal anti‐inflammatory drugs (NSAIDs) have been reported as the second most 
common cause of drug‐induced hypersensitivity reactions, hypersensitivity to aspirin affecting 
from 0.5 to 1.9% of the general population, with greater prevalence in asthmatics or patients 
with chronic urticaria [31, 32]. The NSAID‐induced hypersensitivity has a wide range of 
 clinical manifestations from anaphylaxis or severe bronchospasm developed within minutes 
to delayed‐type responses, appearing after days or weeks. Bronchial asthma, aspirin‐exac‐
erbated respiratory disease (AERD), rhinosinusitis, urticaria are frequently encountered. 
The delayed‐type skin or systemic reactions are very rare and include Stevens‐Johnson 
syndrome, toxic epidermal necrolysis (TEN) and drug reaction with eosinophilia and systemic 
symptoms (DRESS).
The pathogenetic mechanism of NSAID‐induced asthma and AERD is represented by the 
inhibition of COX‐1 (by aspirin and other non‐selective NSAIDs), which triggers a mechanism 
leading to an asthmatic attack or nasal symptoms. Apparently, deprivation of PGE2 may 
lead to activation of inflammatory pathways and a local and systemic generation of cysteinyl 
leucotrienes, the most potent bronchoconstrictors.
Beside aspirin, hypersensitivity reactions have been documented especially in NSAIDs with 
heteroaryl acid group (naproxen, diclofenac, ibuprofen), newer COX‐2 selective compounds 
having a very low incidence of this adverse effect [33].
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3. Drug interactions of NSAIDs
Drug interactions are increasingly becoming a major concern for healthcare providers due to 
the necessity of using multiple drugs for the treatment of complex pathologies [34]. NSAIDs 
are frequently involved in drug‐drug interactions, leading to increased hospitalization and 
health care cost [35].
3.1. Antihypertensives
In normotensive and untreated hypertensive patients, NSAIDs are probably having a weak 
effect on blood pressure. The addition of a NSAID to antihypertensive drugs could reduce 
the efficacy of antihypertensives, with a poor control of blood pressure. Several classes of 
antihypertensives are more prone to suffer this interaction: renin‐angiotensin‐aldosterone 
inhibitors, diuretics, and beta‐blockers. Calcium channel blockers and centrally acting sym‐
patholytic drugs are not affected. Elderly patients with hypertension may suffer significant 
changes in blood pressure control [36].
In addition to effects on blood pressure, there is concern that the interaction NSAID‐
Antihypertensives could increase the risk of acute kidney injury, since both classes have 
renal effects [37].
The pathogenetic mechanisms of these interactions are variable. NSAIDs interfere with the 
angiotensine converting enzyme (ACE) inhibitors directly and indirectly by decreasing renal 
prostaglandin synthesis and by reducing ACE inhibitors‐induced prostaglandin synthesis. 
Also, NSAIDs decrease the efficacy of diuretics by reducing their natriuretic effect. The beta‐
blockers are influenced by the reduction of prostaglandin synthesis and a reduction in plasma 
renin, but their antihypertensive effects are marginally modified [38].
A comprehensive review of clinical data from the USA highlighted that indomethacin, 
naproxen, and piroxicam were associated with clinically significant increases in blood pres‐
sure, especially in patients treated with enalapril [38, 39]. Another US study of hypertensive 
patients, treated with ACEIs, and also receiving ibuprofen (2400 mg/day), nabumetone (2000 
mg/day), or celecoxib (400 mg/day), found that ibuprofen, but not nabumetone or celecoxib, 
increased the mean arterial pressure with 6.5±1.4 mm Hg [40].
Also, considering that aldosterone antagonists (spironolactone) may increase the risk of GI 
bleeding, patients should be informed that the long‐term use of a NSAID could increase the 
probability of GI adverse effects [37].
The same US study found that small but significant increases in blood pressure occurred 
when indomethacin, piroxicam, naproxen, or ibuprofen were introduced in patients treated 
with hydrochlorothiazide or amiloride [38]. Another study examined the effects of ibuprofen 
(2400 mg/day) and naproxen (750 mg/day) on blood pressure in hypertensive patients 
treated with hydrochlorothiazide. After 4 weeks, the effects of NSAIDs on blood pressure 
were considered minor [41].
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In conclusion, hypertensive patients under treatment with ACEIs or hydrochlorothiazide 
should avoid chronic use of NSAIDs [37].
3.2. Antithrombotics
Drug interactions between NSAIDs and antithrombotic medication have been extensively 
studied, as they can generate serious consequences.
The simultaneous administration of NSAIDs and cardioprotective aspirin can result in a 
 competition for access into the active site of COX‐1. Theoretically, this could lead to a reduction 
of aspirin’s irreversible inhibition of platelet COX‐1, with a subsequent reduction of  clinical 
efficacy (prevention of an unwanted thrombotic event). A study on 5208 people found that 
patients taking prophylactic aspirin together with ibuprofen (more than four times per week) 
showed an almost doubled risk for MI, compared with patients taking ibuprofen infrequently 
[42]. Other studies showed different results. A retrospective study on 42,611 patients, including 
8688 cases of MI, found that patients treated with aspirin and any NSAID had a lower risk 
for MI than the ones not taking aspirin and NSAIDs [43]. Another study on 22,071 apparently 
healthy patients showed that regular but not intermittent use of NSAIDs inhibits the clinical 
benefits of aspirin [44].
Despite the conflicting results of these studies, the avoidance of chronic use of NSAIDs in patients 
under treatment with cardioprotective aspirin is advisable. FDA recommends taking ibuprofen 
at least 8 hours before and 30 minutes after aspirin to reduce the likelihood of an interaction [45].
Although NSAIDs do not cause a direct pharmacodynamic interaction with warfarin, con‐
comitant use may increase the probability of GI bleeding [46].
3.3. Antidepressants
In the 1990s, a large number of reports of bleeding disorders associated with selective 
 serotonin reuptake inhibitors (SSRIs) were published, prompting further investigations. 
Although platelets do not synthesize serotonin, they can uptake it from plasma, and therefore 
serotonin may be involved in hemostasis and thrombosis. Thus, at the association of SSRIs 
with NSAIDs, which can also affect platelets, an interaction is possible. Furthermore, a phar‐
macokinetic interaction is possible, considering that some SSRIs inhibit CYP2C9, an enzyme 
involved in the metabolism of ibuprofen and diclofenac [47].
A recent review estimated that the risk of GI bleeding with the use of SSRIs relative to the 
non‐use is 2.6 (95% CI: 1.7–3.8) [48]. Another review of the literature synthesized data from 
four retrospective studies examining the adverse outcomes from the association of SSRIs with 
NSAIDs. Two of the studies concluded that the risk ratio for an upper GI bleeding after the 
association was greater than the additive risk of either drug alone [49].
3.4. Alcohol
Alcohol can favor GI bleeding when consumed in large quantities, so that an additive effect 
with NSAIDs has been documented. A case‐control study using 1224 inpatients found 
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a 2.7‐ fold increase in the risk for GI bleeding in individuals who regularly took ibupro‐
fen and consumed alcohol (95% CI: 1.6–4.4) [50]. Another study using 1083 hospitalized 
patients found that the presence of either NSAIDs use or a history of alcohol abuse led to 
an odds ratio (OR) of 2.9 for severe GI events, while the presence of both risk factors led to an 
OR of 10.2 [51].
3.5. Methotrexate
Several NSAIDs have been found to reduce renal clearance of methotrexate, which could 
generate toxic events (renal failure, pancytopenia), especially at high doses [37]. Recently, a 
Cochrane review stated that using low doses of MTX (under 25 mg weekly, administered sc) 
and NSAIDs will not produce a clinically significant interaction [52].
4. Conclusions
The non‐steroidal anti‐inflammatory drugs (NSAIDs) have a variety of clinical applications 
due to their anti‐inflammatory, analgesic, antipyretic, or antithrombotic effects.
The safety profile of NSAIDs remains positive when used in low doses for the temporary relief 
of pain or fever. In elderly patients, or in those with gastrointestinal or cardiovascular risk 
factors, more caution is necessary in order to avoid the apparition of serious adverse effects.
Patients chronically treated with ACE inhibitors, hydrochlorothiazide, spironolactone, or 
aspirin should be informed about the risks of NSAIDs administration.
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